Compare · MDLN vs NVNO
MDLN vs NVNO
Side-by-side comparison of Medline Inc. (MDLN) and enVVeno Medical Corporation (NVNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NVNO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 6513.6x NVNO ($6.8M).
- Over the past year, MDLN is down 17.1% and NVNO is down 93.1% - MDLN leads by 76.0 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 1 for NVNO).
- MDLN has more recent analyst coverage (25 ratings vs 0 for NVNO).
- Company
- Medline Inc.
- enVVeno Medical Corporation
- Price
- $33.80+0.58%
- $10.69-0.93%
- Market cap
- $44.40B
- $6.8M
- 1M return
- -19.55%
- +5.22%
- 1Y return
- -17.07%
- -93.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2018
- News (4w)
- 20
- 1
- Recent ratings
- 25
- 0
enVVeno Medical Corporation
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based devices to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and works as a replacement venous valve to reduce reflux and venous hypertension, as well as to restore proper directional blood flow back to the heart. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest NVNO
- enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
- Amendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical Corporation
- enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
- enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
- SEC Form 10-Q filed by enVVeno Medical Corporation
- enVVeno Medical Corporation filed SEC Form 8-K: Other Events, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
- enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
- enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System
- SEC Form S-8 filed by enVVeno Medical Corporation